• OFID 2018:5 (Suppl 1) • Poster Abstracts penetration using the ratio of ELF:serum AUC 0-∞ was 33.0% for ASN-1 and 20.3% for ASN-2 following the selected clinical dose of 3,600 mg.
Background. Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae exhibit variable response to treatment with piperacillin-tazobactam. Current clinical practice with piperacillin-tazobactam involves dosing the components simultaneously at a fixed ratio of 8:1 piperacillin to tazobactam. However, it remains unclear whether this ratio is optimal for enzyme inhibition and bactericidal activity. Using a hollowfiber infection model (HFIM), we evaluated the efficacy of various exposures of piperacillin-tazobactam against ESBL-producing Enterobacteriaceae.
Methods. A clinical strain of K. pneumoniae expressing CTX-M-15 was used as a reference isolate. Piperacillin minimum inhibitory concentrations (MIC) were determined using a range of tazobactam concentrations and fitted to an inhibitory E max model. An HFIM was used to simulate and evaluate the impact of escalating tazobactam dosing in the context of a fixed piperacillin exposure (equivalent to 4 g every 8 hours). Serial samples were collected to verify the pharmacokinetic simulations (by LC-MS/MS) and determine bacterial density for up to 120 hours. Measured drug concentrations were incorporated in the E max model to determine the free-time above instantaneous MIC (fT>MICi) associated with each experimental exposure. The target fT>MICi associated with growth suppression was subsequently validated using a clinical strain of E. coli (producing SHV-12) and a second K. pneumoniae (producing CTX-M-15).
Results. For the reference strain, a clinical regimen of 4 g piperacillin and 0.5 g tazobactam administered every 8 hours resulted in a fT > MICi of 39.6% and bacterial regrowth. An exposure equivalent to 1.5 g tazobactam (fT > MICi of 55.1%) was needed to suppress growth. These regrowth findings were validated with the two other ESBL-producers with tazobactam exposures characterized by fT > MICi of 36.8 and 43.8%.
Conclusion. Improved bacterial killing was observed with increasing tazobactam exposures. As a novel PK/PD index, fT > MICi may be used to characterize response to a β-lactamase inhibitor and provide efficacy targets to guide the development and clinical dosing of these inhibitors. 
Background.
Resistance mediated by extended-spectrum β-lactamases (ESBLs) presents a serious challenge in the treatment of Gram-negative pathogens. ESBLs confer resistance to most β-lactams which may be reversed with the addition of an active β-lactamase inhibitor (such as tazobactam, relebactam and avibactam). However, various ESBLs may display different susceptibilities to these inhibitors, which could impact efficacy. We propose a framework for comparing the efficacy of these inhibitors when combined with the same β-lactam.
Methods. Three clinical isolates of K. pneumoniae harboring CTX-M-15 and one E. coli with SHV-12 were used. The susceptibility of each isolate to piperacillin was determined by broth dilution using escalating concentrations of tazobactam, relebactam and avibactam. Similar experiments were subsequently conducted with ceftazidime. The resulting minimum inhibitory concentrations (MICs) were mapped as response to inhibitor concentration using an inhibitory E max model. The best-fit model parameters were compared for each isolate-inhibitor combination.
Results. In all scenarios, MIC reductions were observed in the presence of increasing inhibitor concentrations. The MIC reduction for each isolate was well fitted to inhibitor concentrations (r 2 ≥ 95%). IC 50 estimates reflected the sensitivity of the isolates to each inhibitor, while I max captured the maximum extent of MIC reduction. With piperacillin, IC 50 values ranged from 1.36 to 35.25µg/mL for tazobactam, 2.32-15.82 µg/mL for relebactam and 0.62-2.37 µg/mL for avibactam. I max values were 4.75-6.99, 6.56-9.77 and 7.83-11.22 for tazobactam, relebactam and avibactam, respectively. Similar trends in IC 50 and I max were observed with ceftazidime as the β-lactam.
Conclusion. We illustrated a simple structural model capable of comparing the performance of different inhibitors. This platform may be used to identify the optimal pairing of various β-lactams and β-lactamase inhibitors for individual isolates. VAN has been shown to cause increased incidence of AKI when combined with TZP. The reason is unknown. TEI is a glycopeptide which may be less nephrotoxic. We compared both glycopeptides in combination with TZP or MER for causing AKI.
Methods. A retrospective cohort study was performed between May 2015 and December 2017 in a large tertiary care setting. Evaluation of AKI was made by using RIFLE criteria. Patients ≥18 years were included if they had a baseline serum creatinine available and received one of the combinations tested for at least 48 hours. Exclusion criteria were renal replacement therapy, pregnancy, <48 hours antibiotic therapy and no follow-up.
Results. Overall 456 patients were screened and 379 included in the study. After controlling for residual differences (age, Charlson comorbidity index score, presence of AKI, GFR value, presence of sepsis or septic shock, residing in intensive care unit at the time of antibiotic therapy and number of days of antibiotic therapy), AKI incidence was significantly higher in patients receiving TZP-VAN than those receiving TZP-TEI and also in patients receiving TZP-VAN than those with MER-VAN. No difference
